6978 — Immunotech Biopharm Balance Sheet
0.000.00%
Last trade - 00:00
- HK$1.67bn
- HK$1.97bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 282 | 845 | 353 | 79.5 | 178 |
Net Total Receivables | 0.75 | 0 | — | — | — |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 308 | 884 | 412 | 118 | 214 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 85.3 | 154 | 427 | 527 | 501 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 417 | 1,210 | 1,098 | 879 | 846 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 206 | 31.6 | 180 | 208 | 203 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 248 | 82.7 | 275 | 371 | 673 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 169 | 1,128 | 822 | 508 | 174 |
Total Liabilities & Shareholders' Equity | 417 | 1,210 | 1,098 | 879 | 846 |
Total Common Shares Outstanding |